Give in Honour - Asthma Canada

Asthma Self-Check
Get Help
About Us
What We Do
News & Updates
Resources
- FREE Resources
- Webinars
Get Involved
Donate

Having trouble viewing the donation page? Click here to donate directly!

Instagram

It is with great pleasure that Asthma Canada welco

It is with great pleasure that Asthma Canada welcomes Kim Steele to our Board of Directors. Kim is a strategic and influential drug access and public affairs leader with over 20 years of success in securing public and private reimbursement for innovative medicines across Canada. She has a proven ability to shape drug access and policy to drive regulatory wins across all levels of government. A trusted spokesperson and relationship builder known for aligning diverse stakeholders—including patient organizations, elected officials, and industry leaders— Kim has dedicated her career to improving access and affordability of medicines and care in Canada. Kim is the Director of Advocacy & Community Relations for Cystic Fibrosis Canada and is Vice-Chair of the Board of Directors for Best Medicines Coalition. As someone who lives with asthma and related allergies, she has benefited from Asthma Canada’s programs and services and appreciates the opportunity to contribute to the organization as a director. We’re very pleased to welcome Kim’s expertise to our Board as we advance our mission to improve the lives of people in Canada living with asthma.

Asthma Canada is delighted to welcome Dr. Andreann

Asthma Canada is delighted to welcome Dr. Andreanne Côté to our Board of Directors. Dr. Côté is a clinician-researcher and respirologist at the Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ), and an Associate Professor at Université Laval. She completed her medical degree at the Université de Sherbrooke, followed by residency training in internal medicine and respirology at Université Laval. She also earned a master’s degree in clinical epidemiology from Université Laval. Since 2018, Dr. Côté has been actively engaged in research aimed at improving the management of severe asthma, with a particular emphasis on the use of biomarkers to support treatment personalization. She serves as Vice-Chair of the Asthma Assembly of the Canadian Thoracic Society and is a contributing author on the upcoming national guidelines for severe asthma. Dr. Côté’s leadership and expertise is warmly welcomed to our Board as we continue working to improve the lives of people in Canada living with asthma.

Asthma Canada President & CEO Jeffrey Beach and As

Asthma Canada President & CEO Jeffrey Beach and Asthma Canada Advocate Kimberly Couvillon recently met with Andrew Dowie, MPP for Windsor–Tecumseh, at his constituency office in Windsor. Kimberly, a resident of Windsor, bravely shared the story of her daughter Amber, who tragically lost her life to an asthma attack at just 14 years old in June 2024. We’re grateful to MPP Dowie for taking the time to hear Amber’s story and engage in a meaningful discussion about the urgent policy solutions Asthma Canada is proposing. These include ensuring children and adults living with asthma have access to timely, appropriate care and that Certified Respiratory Educators are included in the investments that the Government is making in primary care across the province. #asthma #windsor andrewdowie

Chronic rhinosinusitis with nasal polyps (CRSwNP)

Chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma frequently coexist and share similar inflammatory pathways. Having both conditions can lead to more severe symptoms, poorer quality of life, and increased difficulty in managing both conditions. Oral Corticosteroids (OCS) are a common and effective medical treatment option for patients with CRSwNP, often used for short-term control of symptoms. Despite their proven short-term efficacy, OCS are also associated with increased risk of short-and long-term adverse effects, with guidelines in respiratory disease recommending limiting use when possible. A recent study by @gsk and Asthma Canada found that that 81% of CRSwNP patients were prescribed OCS at least once in the 24 months prior to starting a biologic treatment with 39% of patients being overexposed to OCS by the time they started a biologic. These findings highlight the need for heightened awareness and education to prevent OCS overexposure and enhance patient care. A huge thanks to Asthma Canada Patient Advocate, Renay Michele Lambert for sharing her story with Pauline Chan and the CTV News team. #asthma #crswnp #nasalpolyps

Follow on Instagram

Helpful links

About Asthma

Get Help

Get Involved

FAQ

Resources

News & Updates

Careers & Volunteer Opportunities

Contact Us



124 Merton St. Unit 401 Toronto, ON M4S 2Z2



1-866-787-4050



info@asthma.ca

Charitable Registration Number:

89853-7048-RR0001

Subscribe

Sign-up to have the latest asthma news and information delivered to your inbox.

2025 © All Rights Reserved | Media | Privacy | Terms of Use